4 Healthcare Stock Stories for Thursday Investment Wellness

 MEI Pharma (NASDAQ: MEIP): Current price $8.64

MEI Has announced the presentation of new data exhibiting the ability of its mitochondrial inhibitor drug candidate, ME-344, to lower tumor burden and delay recurrence in a pre-clinical in vivo model of recurrent epithelial ovarian cancer, which is the most lethal of all gynecologic malignancies. The data were presented by Ayesha Alvero , M.D., Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, on Tuesday at the American Association for Cancer Research Annual Meeting in Washington, DC. MEI is an oncology firm focused on the clinical development of novel therapies for cancer.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

MEIP

Integra LifeSciences Holdings Corporation (NASDAQ:IART): Current price $35.78

The company announced Wednesday that on April 10th it began a voluntary recall of certain products made in its Añasco, Puerto Rico facility between December 2010 and May 2011, and between November 2012 and March 2013. Specific lots of these products, which include DuraGen Dural Graft Matrix products, have been recalled because the company identified that there may have been deviations from approved processes in their production. There have been no reports of adverse patient events due to the products involved in the recall, and Integra continues to manufacture all the affected products in, and distribute from, its Añasco facility.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

IART

Pfizer (NYSE:PFE): Current price $30.54

On Wednesday, Pfizer reported that its experimental pill for advanced breast cancer has been designated as a breakthrough therapy by the FDA. The breakthrough designation, created under legislation enacted in the summer of 2012 to fund and improve operations of the FDA, is meant to accelerate development and review of experimental treatments that are viewed as meaningful advances over current therapies for serious diseases. Palbociclib is being studied as an initial treatment for the largest subgroup of postmenopausal women whose breast cancer is locally advanced or has spread elsewhere in the body.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

PFE

Harvard Bioscience (NASDAQ:HBIO): Current price $4.85

On Wednesday, the firm announced that the planned initial public offering by its wholly-owned regenerative medicine device subsidiary, Harvard Apparatus Regenerative Technology, has been postponed because of market conditions. Harvard Bioscience, a world developer, maker, and marketer of a broad range of tools through which to advance life science research and regenerative medicine, continues to believe that the best path to maximizing value for its shareholders is to separate its regenerative medicine device unit from its profitable core life science research tools division.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

HBIO

Don’t Miss: Here’s Your Cheat Sheet To Obama’s Fiscal 2014 Budget Proposal.

More Articles About:   , , , ,  

More from The Cheat Sheet